




PT IKAPHARMINDO PUTRAMAS Tbk

Pharmaceutical Laboratories

Jl. Pulogadung Raya No. 29, Kawasan Industri Pulogadung, Jakarta Timur 13930 - Indonesia

Phone : +62 21 460 0086/461 4766 (Hunting), Fax : +62 21 460 8865

Email : secretary@ikapharmindo.com, website : www.ikapharmindo.com

Jakarta, 16 September 2026 Nomor : 50/DIR/IX/26 Lampiran : 5 (lima) lembar Kepada Yth.: Otoritas Jasa Keuangan Republik Indonesia ("OJK") Gedung Sumitro Djojohadikusumo Jl. Lapangan Banteng Timur 2-4 Jakarta – 10710 Perihal: Laporan Realisasi Penggunaan Dana Hasil Penawaran Umum PT Ikapharmindo Putramas Tbk per 30 Juni 2026 (Koreksi) Dengan hormat, Dalam rangka memenuhi Peraturan Otoritas Jasa Keuangan Nomor 40 Tahun 2025 tentang Penggunaan Dana Hasil Penawaran Umum dan Surat OJK Nomor S-2113/PM.221/2026 tanggal 04 September 2026, bersama ini kami sampaikan Laporan Realisasi Penggunaan Dana Hasil Penawaran Umum PT Ikapharmindo Putramas Tbk per 30 Juni 2026 (Koreksi). Demikian Laporan Realisasi Penggunaan Dana Hasil Penawaran Umum PT Ikapharmindo Putramas Tbk per 30 Juni 2026 (Koreksi) ini kami kirimkan. Atas perhatian dan kerja sama yang baik, kami ucapkan terima kasih. Hormat kami, PT Ikapharmindo Putramas Tbk	Jakarta, September 16, 2026 No. : 50/DIR/IX/26 Attachment : 5 (five) sheets To: Financial Services Authority ("FSA") Sumitro Djojohadikusumo Building Jl. Lapangan Banteng Timur 2-4 Jakarta – 10710 Regarding: Report for Realization of Proceeds from Public Offering of PT Ikapharmindo Putramas Tbk as of June 30, 2026 (Correction) Dear Sir/Madam, In order to comply with FSA Regulation Number 40 of 2025 regarding Use of Funds from Public Offering and FSA Letter Number S-2113/PM.221/2026 dated September 04, 2026, we herewith would like to convey Report for Realization of Funds from Public Offering of PT Ikapharmindo Putramas Tbk per June 30, 2026 (Correction). Thus we send Report for Realization of Proceeds from Public Offering of PT Ikapharmindo Putramas Tbk per June 30, 2026 (Correction). For your kind attention and cooperation, we say thank you. Sincerely yours, PT Ikapharmindo Putramas Tbk
 PT. IKAPHARMINDO PUTRAMAS Tbk PHARMACEUTICAL LABORATORIES  Ayi Saepudin Direktur dan Corporate Secretary/Director and Corporate Secretary	

Laporan Realisasi Penggunaan Dana Hasil Penawaran Umum / Disclosure Report of Utilization of Public Offering of
PT Ikapharmindo Putramas Tbk / PT Ikapharmindo Putramas Tbk
Per 30 Juni 2026 (Koreksi) / As of June 30, 2026 (Correction)

No. Penawaran Umum / Type of Public Offering	Jenis Penawaran / Effective Date	Nilai Realisasi Hasil Penawaran Umum / Realized Value of Public Offering				Rencana Penggunaan Dana / Plan of Use of Proceeds		Realisasi Penggunaan Dana / Realization of Use of Proceeds		Sisa Dana Hasil Penawaran Umum / Remaining Public Offering Proceeds		Target Penggunaan Dana / Target Timeline for Use of Proceeds
		Jumlah Hasil Penawaran Umum / Total Public Offering Proceeds	Biaya Penawaran Umum / Public Offering Costs	Hasil Bersih / Net Proceeds	Total / Total	Persentase Terhadap Hasil PU / Percentage of Public Offering Proceeds after deducting Public Offering Costs	Total / Total	Persentase Terhadap Hasil PU / Percentage of Public Offering Proceeds after deducting Public Offering Costs	Pos Dalam Laporan Keuangan / Account in Financial Statements	Total / Total	Persentase Terhadap Hasil PU / Percentage of Public Offering Proceeds after deducting Public Offering Costs	Keterangan / Remarks
Penawaran Umum Perdana Saham / Initial Public Offering	8 November 2023 / November 8, 2023	55,593,862,500	3,184,356,255	52,409,506,245	52,409,506,245	100%	50,338,868,514	96,0%	1. Belanja Barang Modal dan Mesin / Capital expenditure and machinery 2. Belanja Modal Kerja / Working capital expenditure	2,070,637,731	4,0%	Sisa dana tersimpan dalam bentuk deposito pada Bank OCBC NISP / Remaining Public Offering Proceeds is saved in deposit form at OCBC NISP Bank
Jumlah / Amount		55,593,862,500	3,184,356,255	52,409,506,245	52,409,506,245	100%	50,338,868,514	96,0%		2,070,637,731	4,0%	

Jakarta, 15 September 2026 / Jakarta, September 16, 2026


PT. IKAPHARMINDO PUTRAMAS Tbk
PHARMACEUTICAL LABORATORIES
Direktur dan Corporate Secretary / Director and Corporate Secretary

Detail Laporan Realisasi Penggunaan Dana Hasil Penawaran Umum / *Detail of Disclosure Report of Utilization of Public Offering of*
PT Ikapharmindo Putramas Tbk / *PT Ikapharmindo Putramas Tbk*
Per 30 Juni 2026 (Koreksi) / *As of June 30, 2026 (Correction)*

a. Rincian Biaya Penawaran Umum / *Description of Public Offering Costs*

Jenis Penawaran Umum / <i>Type of Public Offering</i>	Tanggal Efektif/ <i>Effective Date</i>	Jumlah Hasil Penawaran Umum/ <i>Total Public Offering Proceeds</i>	Biaya Penawaran Umum / <i>Public Offering Costs</i>		
			Uraian Biaya / <i>Costs Description</i>	Jumlah / <i>Amount</i>	Persentase / <i>Percentage</i>
Penawaran Umum Perdana Saham / <i>Initial Public Offering</i>	8 November 2023 / <i>November 8, 2023</i>	55.593.862.500	a. biaya jasa perantara <i>(underwriting fee)</i>	277.969.313	8,73%
			b. biaya jasa penyelenggaraan <i>(management fee)</i>	1.444.061.374	45,35%
			c. biaya jasa penjualan <i>(selling fee)</i>	277.969.313	8,73 %
			d. biaya jasa profesi penunjang pasar modal <i>(capital market supporting profession fee)</i>	749.950.000	23,55%
			e. biaya jasa lembaga penunjang pasar modal <i>(capital market supporting institution fee)</i>	106.178.000	3,40%
			f. biaya jasa konsultasi keuangan <i>(financial advisory fee)</i>	0	0%
			g. Biaya lain-lain yang dapat dibebankan langsung sebagai biaya emisi <i>(Other fees which can be directly attributed as securities issuance fees)</i>	326.228.255	10,24%
			Total / <i>Total</i>	3.184.356.255	100%

Jakarta, 16 September 2026 / *Jakarta, September 16, 2026*


PT. IKAPHARMINDO PUTRAMAS Tbk
PHARMACEUTICAL LABORATORIES
Aye Saepudin
Direktur dan Corporate Secretary / *Director and Corporate Secretary*

Detail Laporan Realisasi Penggunaan Dana Hasil Penawaran Umum / Detail of Disclosure Report of Utilization of Public Offering of
PT Ikapharmindo Putramas Tbk/PT Ikapharmindo Putramas Tbk
Per 30 Juni 2026 (koreksi)/As of June 30, 2026 (Correction)

b. Rincian Rencana dan Realisasi Penggunaan Dana Hasil Penawaran Umum / Description of Plan and Realization of Use of Proceeds

Jenis Penawaran Efektif/ Umum / Type of Public Offering	Tanggal Efektif/ Effective Date	Rencana Penggunaan Dana/ Plan of Use of Proceeds								Persentase Rencana Penggunaan Dana terhadap Nilai Hasil Penawaran Umum / Percentage of Plan of Use of Proceeds against the Net Proceeds of the Realized Value of Public Offering	Realisasi Penggunaan Dana/Realization of Use of Proceeds								Persentase Realisasi terhadap Nilai Hasil Penawaran Umum / Percentage of Realization of Use of Proceeds against the Net Proceeds of the Realized Value of Public Offering	Deviasi/ Deviation	Keterangan /Remarks		
		Level 1	Level 2	Level 3	Level 4		Level 1	Level 2	Level 3	Level 4													
		Deskripsi /Description	Nilai/ Value	Deskripsi /Description	Nilai/ Value	Deskripsi /Description	Nilai/ Value	Deskripsi /Description	Nilai/ Value	Deskripsi /Description	Nilai/ Value	Deskripsi /Description	Nilai/ Value	Deskripsi /Description	Nilai/ Value	Deskripsi /Description	Nilai/ Value	Deskripsi /Description	Nilai/ Value	Deskripsi /Description	Nilai/ Value	Deskripsi /Description	Nilai/ Value
Penawaran Umum Perdana Saham/ Initial Public Offering	8 November 2023 / November 8, 2023	Belanja Barang Modal dan Mesin / Capital Expenditure and Machinery	8.731, 423,740								100%	Belanja Barang Modal dan Mesin / Capital Expenditure and Machinery	6.550, 785, 009										76,3% 23,7% Bulan Juli 2026 /July 2026
		Belanja Modal Kerja/ Working Capital Expenditure	43,678, 082,505								100%	Belanja Modal Kerja/ Working Capital Expenditure	43,678, 082, 505										100% 0,0%

[illegible]

Jakarta, 16 September 2026/Jakarta, September 16, 2026

~~AYI Saep~~

AYI Saepudin
PTIKS PHARMINDO PUTRAMAS Tbk
FARMACEUTICAL LABORATORIES

**Detail Laporan Realisasi Penggunaan Dana Hasil Penawaran Umum / Detail of Disclosure Report of Utilization of Public Offering of
PT Ikapharmindo Putramas Tbk/ PT Ikapharmindo Putramas Tbk
Per 30 Juni 2026 (Koreksi)/ As of June 30, 2026 (Correction)**

c. Rincian Penempatan Sisa Dana/ Details of the Placement of Remaining Proceeds

Jenis Penawaran Umum / Type of Public Offering	Tanggal Efektif/ Effective Date	Sisa Dana/ Remaining Proceeds	Penempatan/ Placement	Jangka Waktu Penempatan/ Placement Period	Tingkat Suku Bunga atau Imbal Hasil/ Interest Rate or Yield	Hubungan dengan Perusahaan/ Relationship with the Company
Penawaran Umum Perdana Saham / Initial Public Offering	8 November 2023 / November 8, 2023	2.070.637.731	Rekening Deposito/ Deposit Account	14 hari / 14 days	3%	non afiliasi / not affiliated

Jakarta, 16 September 2026/Jakarta, September 16, 2026


PT. IKAPHARMINDO PUTRAMAS Tbk
PHARMACEUTICAL LABORATORIES
 Ayu Sapudin
 Direktur dan Corporate Secretary/Director and Corporate Secretary